دورية أكاديمية
أعرض في EDS

The management of pemphigus vulgaris and mucous membrane pemphigoid in a joint oral medicine and dermatology clinic: a five-year narrative review.

التفاصيل البيبلوغرافية
العنوان: The management of pemphigus vulgaris and mucous membrane pemphigoid in a joint oral medicine and dermatology clinic: a five-year narrative review.
المؤلفون: Davis G; Specialty Registrar and Honorary Clinical Lecturer, Department of Oral Medicine, Bristol Dental Hospital, Lower Maudlin Street, Bristol, BS1 2LY, UK., Hathway R; Specialty Registrar and Honorary Clinical Lecturer, Department of Oral Medicine, Bristol Dental Hospital, Lower Maudlin Street, Bristol, BS1 2LY, UK., Shipley D; Consultant Dermatologist and Honorary Senior Clinical Lecturer, Department of Dermatology, Bristol Royal Infirmary, 1 Marlborough Hill Pl, Bristol, BS2 8HA, UK., Staines K; Consultant and Honorary Professor in Oral Medicine, Department of Oral Medicine, Bristol Dental Hospital, Lower Maudlin Street, Bristol, BS1 2LY, UK; Bristol Dental School, 1 Trinity Quay, Avon Street, Bristol, BS2 OPT, UK. konrad.staines@bristol.ac.uk.
المصدر: British dental journal [Br Dent J] 2024 Feb; Vol. 236 (4), pp. 311-316. Date of Electronic Publication: 2024 Feb 23.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: British Dental Journal Country of Publication: England NLM ID: 7513219 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5373 (Electronic) Linking ISSN: 00070610 NLM ISO Abbreviation: Br Dent J Subsets: MEDLINE
أسماء مطبوعة: Publication: London : British Dental Journal
Original Publication: London.
مواضيع طبية MeSH: Dermatology* , Pemphigoid, Benign Mucous Membrane*/diagnosis , Pemphigoid, Benign Mucous Membrane*/therapy , Pemphigoid, Bullous*/drug therapy , Pemphigus*/therapy , Oral Medicine*, Humans ; Mucous Membrane
مستخلص: Pemphigus disease and mucous membrane pemphigoid are autoimmune blistering diseases (AIBDs) which may involve both oral and extra-oral tissues. The Bristol Joint Oral Medicine and Dermatology Combined Clinic was set up in 2014, with the primary aim of improving the standard of care for patients with AIBDs. This interdisciplinary approach aimed to address the medical management challenges due to the multisite nature of these AIBDs.We present a narrative report of the clinical work undertaken within this clinic, focused on the management of this patient cohort within a five-year span (2017-2022). This report outlines the multisite nature of AIBDs and the range of topical and systemic treatments that were employed to achieve adequate disease control and optimise outcomes for patients. We reflect on the experiential benefits of this multidisciplinary clinic extended beyond immediate patient benefits to areas such as specialist training, both from a dermatologist's and oral physician's perspective.
(© 2024. The Author(s).)
References: Lamberts A, Euverman H I, Terra J B, Jonkman M F, Horváth B. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Front Immunol 2018; 9: 248.
Carey B, Setterfield J. Mucous membrane pemphigoid and oral blistering diseases. Clin Exp Dermatol 2019; 44: 732-739.
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.
Chan L S, Ahmed A R, Anhalt G J et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370-379.
Kasperkiewicz M, Kowalewski C, Jabłońska S. Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol 2014; 70: 780-787.
Buonavoglia A, Leone P, Dammacco R et al. Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy. Autoimmun Rev 2019; 18: 349-358.
Harman K E, Brown D, Exton L S et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol 2017; 177: 1170-1201.
Langan S M, Smeeth L, Hubbard R, Fleming K M, Smith C J, West J. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: 180.
Rosi-Schumacher M, Baker J, Waris J, Seiffert-Sinha K, Sinha A A. Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front Immunol 2023; 14: 1159351.
Broussard K C, Leung T G, Moradi A, Thorne J E, Fine J-D. Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Clin Dermatol 2016; 34: 205-213.
Kasperkiewicz M, Ellebrecht C T, Takahashi H et al. Pemphigus. Nat Rev Dis Primers 2017; 3: 17026.
Kridin K, Sagi S Z, Bergman R. Mortality and Cause of Death in Patients with Pemphigus. Acta Derm Venereol 2017; 97: 607-611.
Joly P, Horvath B, Patsatsi A et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020; 34: 1900-1913.
Groves R W. Pemphigus: a brief review. Clin Med (Lond) 2009; 9: 371-375.
Ahmed A R, Spigelman Z, Cavacini L A, Posner M R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-1779.
NHS England. Clinical Commissioning Policy: Rituximab for Immunobullous Disease. 2021. Available at https://www.england.nhs.uk/wp-content/uploads/2021/06/cc-policy-rituximab-for-immonobullous-disease-ocular-v2.pdf (accessed January 2024).
Zillikens D, Wever S, Roth A, Weidenthaler-Barth B, Hashimoto T, Bröcker E B. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995; 131: 957-958.
Bernard P, Vaillant L, Labeille B et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48-52.
Schmidt E, Rashid H, Marzano A V et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. J Eur Acad Dermatol Venereol 2021; 35: 1926-1948.
Parker S R, MacKelfresh J. Autoimmune blistering diseases in the elderly. Clin Dermatol 2011; 29: 69-79.
Du G, Patzelt S, van Beek N, Schmidt E. Mucous membrane pemphigoid. Autoimmun Rev 2022; 21: 103036.
Taylor J, McMillan R, Shephard M et al. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: 161-171.
Rashid H, Lamberts A, Borradori L et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I. J Eur Acad Dermatol Venereol 2021; 35: 1750-1764.
Daniel B S, Murrell D F. Review of autoimmune blistering diseases: the Pemphigoid diseases. J Eur Acad Dermatol Venereol 2019; 33: 1685-1694.
Finn D J, Graham C, Holt D J, Kelly R, Rajlawat B P, Yesudian P D. Management of mucous membrane pemphigoid in a joint oral medicine-dermatology clinic. Clin Exp Dermatol 2020; 45: 685-690.
Staines K, Hampton P J. Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 49-56.
NHS England. Dermatology: GIRFT Programme National Specialty Report. 2021. Available at https://gettingitrightfirsttime.co.uk/girft-reports/ (accessed January 2024).
Theodorakopoulou E, Dalamaga M, Katsimbri P, Boumpas D T, Papadavid E. How does the joint dermatology-rheumatology clinic benefit both patients and dermatologists? Dermatol Ther 2020; 33: 13283.
تواريخ الأحداث: Date Created: 20240222 Date Completed: 20240226 Latest Revision: 20240422
رمز التحديث: 20240423
مُعرف محوري في PubMed: PMC10883883
DOI: 10.1038/s41415-024-7074-8
PMID: 38388610
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5373
DOI:10.1038/s41415-024-7074-8